5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Neoplasms O
: O
Preexisting O
malignancy O
should O
be O
inactive O
and O
its O
treatment O
complete O
prior O
to O
starting O
EGRIFTA O
( O
r O
) O
therapy O
. O

( O
5.1 O
) O
* O
Elevated O
IGF-1 O
: O
Monitor O
regularly O
in O
all O
patients O
. O

Consider O
discontinuation O
in O
patients O
with O
persistent O
elevations O
. O

( O
5.2 O
) O
* O
Fluid O
retention O
: O
May O
include O
edema O
, O
arthralgia O
, O
and O
carpal O
tunnel O
syndrome O
. O

( O
5.3 O
) O
* O
Glucose O
intolerance O
: O
May O
develop O
with O
EGRIFTA O
( O
r O
) O
use O
. O

Evaluate O
glucose O
status O
prior O
to O
and O
during O
therapy O
with O
EGRIFTA O
( O
r O
) O
. O

( O
5.4 O
) O
* O
Hypersensitivity O
reactions O
( O
e.g. O
, O
rash O
, O
urticaria O
) O
: O
Advise O
patients O
to O
seek O
immediate O
medical O
attention O
if O
suspected O
. O

( O
5.5 O
) O
* O
Injection O
site O
reactions O
: O
Advise O
patients O
to O
rotate O
sites O
. O

( O
5.6 O
) O
* O
Acute O
critical O
illness O
: O
Consider O
discontinuation O
. O

( O
5.7 O
) O
5.1 O
Neoplasms O
EGRIFTA O
( O
r O
) O
induces O
the O
release O
of O
endogenous O
growth O
hormone O
( O
GH O
) O
, O
a O
known O
growth O
factor O
. O

Thus O
, O
patients O
with O
active O
malignancy B-Not_AE_Candidate
should O
not O
be O
treated O
with O
EGRIFTA O
( O
r O
) O
[ O
see O
Contraindications O
( O
4.2 O
) O
] O
. O

For O
patients O
with O
a O
history O
of O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
malignant I-Not_AE_Candidate
neoplasms I-Not_AE_Candidate
, O
EGRIFTA O
( O
r O
) O
therapy O
should O
be O
initiated O
after O
careful O
evaluation O
of O
the O
potential O
benefit O
of O
treatment O
. O

For O
patients O
with O
a O
history O
of O
treated O
and O
stable O
malignancies B-Not_AE_Candidate
, O
EGRIFTA O
( O
r O
) O
therapy O
should O
be O
initiated O
only O
after O
careful O
evaluation O
of O
the O
potential O
benefit O
of O
treatment O
relative O
to O
the O
risk O
of O
re B-NonOSE_AE
- I-NonOSE_AE
activation I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
underlying I-NonOSE_AE
malignancy I-NonOSE_AE
. O

In O
addition O
, O
the O
decision O
to O
start O
treatment O
with O
EGRIFTA O
( O
r O
) O
should O
be O
considered O
carefully O
based O
on O
the O
increased O
background O
risk O
of O
malignancies B-Not_AE_Candidate
in O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
patients O
. O

5.2 O
Elevated O
IGF-1 O
EGRIFTA O
( O
r O
) O
stimulates O
GH O
production O
and O
increases B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
IGF I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. O

Given O
that O
IGF-1 O
is O
a O
growth O
factor O
and O
the O
effect O
of O
prolonged O
elevations B-NonOSE_AE
in I-NonOSE_AE
IGF I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
levels O
on O
the O
development O
or O
progression B-NonOSE_AE
of I-NonOSE_AE
malignancies I-NonOSE_AE
is O
unknown O
, O
IGF-1 O
levels O
should O
be O
monitored O
closely O
during O
EGRIFTA O
( O
r O
) O
therapy O
. O

Careful O
consideration O
should O
be O
given O
to O
discontinuing O
EGRIFTA O
( O
r O
) O
in O
patients O
with O
persistent B-NonOSE_AE
elevations I-NonOSE_AE
of I-NonOSE_AE
IGF I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
levels I-NonOSE_AE
( O
e.g. O
, O
> O
3 O
SDS O
) O
, O
particularly O
if O
the O
efficacy O
response O
is O
not O
robust O
( O
e.g. O
, O
based O
on O
visceral O
adipose O
tissue O
changes O
measured O
by O
waist O
circumference O
or O
CT O
scan O
) O
. O

During O
the O
clinical O
trials O
, O
patients O
were O
monitored O
every O
three O
months O
. O

Among O
patients O
who O
received O
EGRIFTA O
( O
r O
) O
for O
26 O
weeks O
, O
47.4 O
% O
had O
IGF B-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
standard I-OSE_Labeled_AE
deviation I-OSE_Labeled_AE
scores I-OSE_Labeled_AE
( O
SDS O
) O
, O
and O
35.6 O
% O
had O
SDS O
> O
3 O
, O
with O
this O
effect O
seen O
as O
early O
as O
13 O
weeks O
of O
treatment O
. O

Among O
those O
patients O
who O
remained O
on O
EGRIFTA O
( O
r O
) O
for O
a O
total O
of O
52 O
weeks O
, O
at O
the O
end O
of O
treatment O
33.7 O
% O
had O
IGF B-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
SDS I-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
and O
22.6 O
% O
had O
IGF B-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
SDS I-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
. O

5.3 O
Fluid O
Retention O
Fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
may O
occur O
during O
EGRIFTA O
( O
r O
) O
therapy O
and O
is O
thought O
to O
be O
related O
to O
the O
induction O
of O
GH O
secretion O
. O

It O
manifests O
as O
increased B-NonOSE_AE
tissue I-NonOSE_AE
turgor I-NonOSE_AE
and O
musculoskeletal B-NonOSE_AE
discomfort I-NonOSE_AE
resulting O
in O
a O
variety O
of O
adverse O
reactions O
( O
e.g O
. O

edema B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
carpal B-NonOSE_AE
tunnel I-NonOSE_AE
syndrome I-NonOSE_AE
) O
which O
are O
either O
transient O
or O
resolve O
with O
discontinuation O
of O
treatment O
. O

5.4 O
Glucose O
Intolerance O
EGRIFTA O
( O
r O
) O
treatment O
may O
result O
in O
glucose B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
. O

During O
the O
Phase O
3 O
clinical O
trials O
, O
the O
percentages O
of O
patients O
with O
elevated B-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
( O
> O
= O
6.5 O
% O
) O
from O
baseline O
to O
Week O
26 O
were O
4.5 O
% O
and O
1.3 O
% O
in O
the O
EGRIFTA O
( O
r O
) O
and O
placebo O
groups O
, O
respectively O
. O

An O
increased O
risk O
of O
developing O
diabetes B-OSE_Labeled_AE
with O
EGRIFTA O
( O
r O
) O
( O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
clevel I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
) O
relative O
to O
placebo O
was O
observed O
[ O
intent-to-treat O
hazard O
odds O
ratio O
of O
3.3 O
( O
CI O
1.4 O
, O
9.6 O
) O
] O
. O

Therefore O
, O
glucose O
status O
should O
be O
carefully O
evaluated O
prior O
to O
initiating O
EGRIFTA O
( O
r O
) O
treatment O
. O

In O
addition O
, O
all O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
should O
be O
monitored O
periodically O
for O
changes O
in O
glucose O
metabolism O
to O
diagnose O
those O
who O
develop O
impaired B-NonOSE_AE
glucose I-NonOSE_AE
tolerance I-NonOSE_AE
or O
diabetes B-NonOSE_AE
. O

Diabetes B-NonOSE_AE
is O
a O
known O
cardiovascular O
risk O
factor O
and O
patients O
who O
develop O
glucose B-NonOSE_AE
intolerance I-NonOSE_AE
have O
an O
elevated O
risk O
for O
developing O
diabetes B-NonOSE_AE
. O

Caution O
should O
be O
exercised O
in O
treating O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
patients I-Not_AE_Candidate
with I-Not_AE_Candidate
lipodystrophy I-Not_AE_Candidate
with O
EGRIFTA O
( O
r O
) O
if O
they O
develop O
glucose B-NonOSE_AE
intolerance I-NonOSE_AE
or O
diabetes B-NonOSE_AE
, O
and O
careful O
consideration O
should O
be O
given O
to O
discontinuing O
EGRIFTA O
( O
r O
) O
treatment O
in O
patients O
who O
do O
not O
show O
a O
clear O
efficacy O
response O
as O
judged O
by O
the O
degree O
of O
reduction O
in O
visceral O
adipose O
tissue O
by O
waist O
circumference O
or O
CT O
scan O
measurements O
. O

Since O
EGRIFTA O
( O
r O
) O
increases B-OSE_Labeled_AE
IGF I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
, O
patients O
with O
diabetes B-Not_AE_Candidate
who O
are O
receiving O
ongoing O
treatment O
with O
EGRIFTA O
( O
r O
) O
should O
be O
monitored O
at O
regular O
intervals O
for O
potential O
development O
or O
worsening O
of O
retinopathy O
. O

5.5 O
Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
may O
occur O
in O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
. O

Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
3.6 O
% O
of O
patients O
with O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
associated I-Not_AE_Candidate
lipodystrophy I-Not_AE_Candidate
treated O
with O
EGRIFTA O
( O
r O
) O
in O
the O
Phase O
3 O
clinical O
trials O
. O

These O
reactions O
included O
pruritus B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
other O
rash B-OSE_Labeled_AE
. O

In O
cases O
of O
suspected O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
, O
patients O
should O
be O
advised O
to O
seek O
prompt O
medical O
attention O
and O
treatment O
with O
EGRIFTA O
( O
r O
) O
should O
be O
discontinued O
immediately O
. O

5.6 O
Injection O
Site O
Reactions O
EGRIFTA O
( O
r O
) O
treatment O
may O
cause O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
pruritus O
, O
pain O
, O
irritation O
, O
and O
bruising O
. O

The O
incidence O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
24.5 O
% O
in O
EGRIFTA O
( O
r O
) O
-treated O
patients O
and O
14.4 O
% O
in O
placebo-treated O
patients O
during O
the O
first O
26 O
weeks O
of O
treatment O
in O
the O
Phase O
3 O
clinical O
trials O
. O

For O
patients O
who O
continued O
EGRIFTA O
( O
r O
) O
for O
an O
additional O
26 O
weeks O
, O
the O
incidence O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
6.1 O
% O
. O

In O
order O
to O
reduce O
the O
incidence O
of O
injection B-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
, O
it O
is O
recommended O
to O
rotate O
the O
site O
of O
injection O
to O
different O
areas O
of O
the O
abdomen O
. O

5.7 O
Acute O
Critical O
Illness O
Increased B-NonOSE_AE
mortality I-NonOSE_AE
in O
patients O
with O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illness I-Not_AE_Candidate
due O
to O
complications O
following O
open B-Not_AE_Candidate
heart I-Not_AE_Candidate
surgery I-Not_AE_Candidate
, O
abdominal B-Not_AE_Candidate
surgery I-Not_AE_Candidate
or O
multiple B-Not_AE_Candidate
accidental I-Not_AE_Candidate
trauma I-Not_AE_Candidate
, O
or O
those O
with O
acute B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
failure I-Not_AE_Candidate
has O
been O
reported O
after O
treatment O
with O
pharmacologic O
amounts O
of O
growth O
hormone O
. O

EGRIFTA O
( O
r O
) O
has O
not O
been O
studied O
in O
patients O
with O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illness I-Not_AE_Candidate
. O

Since O
EGRIFTA O
( O
r O
) O
stimulates B-NonOSE_AE
growth I-NonOSE_AE
hormone I-NonOSE_AE
production I-NonOSE_AE
, O
careful O
consideration O
should O
be O
given O
to O
discontinuing O
EGRIFTA O
( O
r O
) O
in O
critically O
ill O
patients O
. O

